Macrocyclic CDK9 Inhibitors for Selective Activity and Reduced Adverse Events
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK9 inhibitors lack selectivity and efficacy, leading to high adverse event rates in clinical practice for treating diseases associated with dysregulated CDK9 kinase activity.
Innovation Solution
Development of a group of compounds represented by formula (I) that act as selective inhibitors of CDK9 kinase activity, including specific structural variations and synthesis methods such as nucleophilic substitution, Buchwald-Hartwig coupling, and intramolecular olefin ring-closing metathesis reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule CDK inhibitors are used to inhibit CDK9 kinase activity, then CDK9 inhibition is achieved, but selectivity for specific CDKs is lacking leading to high adverse event rates
Solution Approach 1:
The macrocyclic compound is designed with specific local structural features including a pyrimidine core with particular substituent patterns (R1, R2, R3 groups) and a macrocyclic framework that creates unique spatial and electronic properties. These localized structural characteristics enable selective binding to CDK9's ATP-binding pocket while excluding other CDK isoforms, thereby achieving high selectivity and reducing adverse events associated with off-target inhibition.
Solution Approach 2:
The invention changes key molecular parameters by transitioning from small molecule inhibitors to macrocyclic compounds with specific structural parameters: molecular weight, ring size, substituent positions, and stereochemistry. These parameter changes fundamentally alter the binding profile and selectivity of the inhibitor, allowing preferential binding to CDK9 over other CDK family members, thus resolving the selectivity-adverse event contradiction.
2Reliability
If non-selective CDK inhibitors are used to treat diseases associated with dysregulated CDK9 activity, then broad CDK inhibition is achieved, but efficacy for specific CDK9-mediated diseases is reduced
Solution Approach 1:
The macrocyclic compound incorporates specific local structural elements (pyrimidine core with defined substituents, macrocyclic framework geometry) that create a binding interface highly complementary to CDK9's active site. This localized structural optimization ensures potent and selective inhibition of CDK9-mediated transcriptional processes, directly improving efficacy for CDK9-driven diseases while avoiding the dilution of effect that occurs with non-selective inhibitors.
3Ease of manufacture
If small molecule CDK inhibitors are developed to target CDK9, then the development process is simpler, but the inhibitors lack selectivity and show high adverse event rates
Solution Approach 1:
The invention systematically optimizes multiple molecular parameters simultaneously: macrocyclic ring size and conformation, pyrimidine substituent types and positions (R1, R2, R3), stereochemical configuration, and overall molecular rigidity. These coordinated parameter changes create a compound with optimal selectivity and safety profile for CDK9 inhibition, transforming the simple but non-selective small molecule approach into a sophisticated macrocyclic structure with precisely tuned properties.
Data Source
AI summary
The present disclosure provides a compound represented by formula (I), a pharmaceutical composition thereof, and a use thereof in treating and/or preventing diseases or disorders related to CDK9 kinase activity.